Clinical trial of alprostadil combined with metformin in the treatment of diabetic nephropathy
10.3760/cma.j.cn121382-20211026-00206
- VernacularTitle:前列地尔联合二甲双胍治疗糖尿病肾病的临床研究
- Author:
Hu YANG
1
;
Li KANG
;
Li WANG
;
Zhijie XUE
Author Information
1. 天津医科大学第二医院肾内科，天津 300211
- Keywords:
Alprostadil;
Metformin;
Diabetic nephropathy;
Cyclic adenosine monophosphate;
Protein kinase A
- From:
International Journal of Biomedical Engineering
2022;45(2):125-129,156
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of alprostadil combined with metformin in the treatment of diabetic nephropathy.Methods:50 cases of diabetic nephropathy patients were enrolled and then divided equally into the observation group and the control group. The patients in the control group were treated with conventional therapy and metformin, and the patients in the observation group were treated with alprostadil on the basis of the treatment of the control group. Compare the glycemic index, lipid index, renal function index, inflammatory response index, and oxidative stress response index of the two groups of patients before and after the 4-week treatment. The ratio of the number of effective cases (significant + effective) to the total number of cases, i.e., the total effective rate, was used to characterize the treatment effect.Results:The total effective rate in the observation group was higher than that in the control group (88.00% vs. 60.00%, P<0.05). After the 4-week treatment, no adverse effects occurred in either group. Compared with the control group, patients in the observation group had higher fasting blood glucose (FBG), glycosylated hemoglobin(HbA1c), mean blood glucose(MBG), blood glucose fluctuation rate(BGFR), standard deviation of blood glucose(SDBG), triglyceride(TC), total cholesterol(TG), high-density lipoprotein(HDL), low-density lipoprotein(LDL), serum creatinine(Scr), urinary microalbumin(UmALB), glomerular filtration rate(eGFR), albumin/creatinine ratio(ACR), cyclic adenosine monophosphate(cAMP), renin, protein kinase(PKA), epinephrine (E), angiotensin-converting enzyme inhibitor Ⅱ(ACEI Ⅱ), and norepinephrine(NE) were improved(all P<0.05). Conclusions:The effect of alprostadil combined with metformin in the treatment of diabetic nephropathy is accurate, safe, and reliable.
